Drug intelligence / Profile preview

Mixed berries

Development stage: Preclinical
Modality: Small Molecules
Administration: Oral

Overview

Mixed berries, specifically a composite of strawberry and red raspberry, are a dietary supplement being investigated for their potential to ameliorate inflammation. Their mechanism of action is believed to involve interactions between their polyphenol content, including anthocyanins and ellagitannins, and the human gut microbiome, leading to changes in systemic and gut inflammation, host- and microbial-derived metabolite pools, and gut microbiome alterations.

Beyond the preview

Go deeper on Mixed berries.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Mixed berries.

Explore the full profile